• Anesthesiology · Feb 2017

    Randomized Controlled Trial Multicenter Study

    Intravenous Amisulpride for the Prevention of Postoperative Nausea and Vomiting: Two Concurrent, Randomized, Double-blind, Placebo-controlled Trials.

    The D2/D3 antagonist amisulpride reduces post-operative nausea and vomiting in moderate-to-high PONV risk adults by 20%.

    • Tong J Gan, Peter Kranke, Harold S Minkowitz, Sergio D Bergese, Johann Motsch, Leopold Eberhart, David G Leiman, Timothy I Melson, Dominique Chassard, Anthony L Kovac, Keith A Candiotti, Gabriel Fox, and Pierre Diemunsch.
    • From the Department of Anesthesiology, Stony Brook University Medical Center, Stony Brook, New York (T.J.G.); Department of Anaesthesia and Critical Care, University Hospitals of Würzburg, Würzburg, Germany (P.K.); Department of Anesthesiology, Memorial Hermann Memorial City Hospital, Houston, Texas (H.S.M.); Department of Anesthesiology, Wexner Medical Center at The Ohio State University, Columbus, Ohio (S.D.B.); Department of Anesthesiology, Universitätsklinikum Heidelberg, Heidelberg, Germany (J.M.); Department of Anaesthesiology and Intensive Care, Philipps University Marburg, Marburg, Germany (L.E.); Department of Anesthesiology, Christus St John Hospital, Nassau Bay, Texas (D.G.L.); Department of Anesthesiology, Helen Keller Hospital, Sheffield, Alabama (T.I.M.); Service d'Anesthésie, Hôpital Mère Enfant, Bron, France (D.C.); Department of Anesthesiology, University of Kansas Medical Center, Kansas City, Kansas (A.L.K.); Department of Anesthesiology, Pain Management and Perioperative Medicine, University of Miami, Miller School of Medicine, Miami, Florida (K.A.C.); Clinical Development Department, Acacia Pharma Ltd, Cambridge, United Kingdom (G.F.); and Department of Anesthesiology and Intensive Care, University Hospital of Hautepierre, Strasbourg, France (P.D.).
    • Anesthesiology. 2017 Feb 1; 126 (2): 268-275.

    BackgroundTwo essentially identical, randomized, double-blind, placebo-controlled, parallel-group phase III studies evaluated the efficacy of intravenous amisulpride, a dopamine D2/D3 antagonist, in the prevention of postoperative nausea and vomiting in adult surgical patients.MethodsAdult inpatients undergoing elective surgery during general anesthesia and having at least two of the four Apfel risk factors for postoperative nausea and vomiting were enrolled at 9 U.S. and 10 European sites. A single 5-mg dose of amisulpride or matching placebo was given at induction of anesthesia. The primary endpoint was complete response, defined as no vomiting/retching and no use of antiemetic rescue medication in the 24-h postoperative period. Nausea incidence was a secondary endpoint.ResultsAcross the two studies, 689 patients were randomized and dosed with study medication, of whom 626 were evaluable per protocol. In the U.S. study, 46.9% (95% CI, 39.0 to 54.9) of patients achieved complete response in the amisulpride group compared to 33.8% (95% CI, 26.2 to 42.0) in the placebo group (P = 0.026). In the European study, complete response rates were 57.4% (95% CI, 49.2 to 65.3) for amisulpride and 46.6% (95% CI, 38.8 to 54.6) for placebo (P = 0.070). Nausea occurred less often in patients who received amisulpride than those who received placebo. There was no clinically significant difference in the safety profile of amisulpride and placebo; in particular, there were no differences in terms of QT prolongation, extrapyramidal side effects, or sedation.ConclusionsOne of the two trials demonstrated superiority, while pooling both in a post hoc change to the plan of analysis supported the hypothesis that amisulpride was safe and superior to placebo in reducing the incidence of postoperative nausea and vomiting in a population of adult inpatients at moderate to high risk of postoperative nausea and vomiting.


      Add institutional full text...



    Always take conclusions with a grain of salt when researchers change their study plan after data collection in order to reach statistical significance, although in this study it may have been necessary due to the lower pre-intervention nausea rate in the European subjects.

    Daniel Jolley  Daniel Jolley

    The D2/D3 antagonist amisulpride reduces post-operative nausea and vomiting in moderate-to-high PONV risk adults by 20%.

    Daniel Jolley  Daniel Jolley
    Do you have a pearl, summary or comment to save or share?
    250 characters remaining
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..